These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 28443355)
41. Improving Current Treatments for Schizophrenia. Maric NP; Jovicic MJ; Mihaljevic M; Miljevic C Drug Dev Res; 2016 Nov; 77(7):357-367. PubMed ID: 27633376 [TBL] [Abstract][Full Text] [Related]
42. Effects of antipsychotic D2 antagonists on long-term potentiation in animals and implications for human studies. Price R; Salavati B; Graff-Guerrero A; Blumberger DM; Mulsant BH; Daskalakis ZJ; Rajji TK Prog Neuropsychopharmacol Biol Psychiatry; 2014 Oct; 54():83-91. PubMed ID: 24819820 [TBL] [Abstract][Full Text] [Related]
43. Blockade of dopamine D₃ but not D₂ receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment. Watson DJ; Marsden CA; Millan MJ; Fone KC Int J Neuropsychopharmacol; 2012 May; 15(4):471-84. PubMed ID: 21414250 [TBL] [Abstract][Full Text] [Related]
44. Rationale for Adjunctive Treatment Targeting Multiple Mechanisms in Schizophrenia. Kinon BJ; Leucht S; Tamminga C; Breier A; Marcus R; Paul SM J Clin Psychiatry; 2024 Aug; 85(3):. PubMed ID: 39196873 [No Abstract] [Full Text] [Related]
45. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials. Leucht S Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S15-20. PubMed ID: 14972080 [TBL] [Abstract][Full Text] [Related]
46. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade. Auclair AL; Kleven MS; Besnard J; Depoortère R; Newman-Tancredi A Neuropsychopharmacology; 2006 Sep; 31(9):1900-9. PubMed ID: 16421514 [TBL] [Abstract][Full Text] [Related]
47. Perospirone. SM 9018. Drugs R D; 1999 Jul; 2(1):60-2. PubMed ID: 10610286 [No Abstract] [Full Text] [Related]
48. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Miyamoto S; Duncan GE; Marx CE; Lieberman JA Mol Psychiatry; 2005 Jan; 10(1):79-104. PubMed ID: 15289815 [TBL] [Abstract][Full Text] [Related]
49. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Grunder G; Carlsson A; Wong DF Arch Gen Psychiatry; 2003 Oct; 60(10):974-7. PubMed ID: 14557141 [TBL] [Abstract][Full Text] [Related]
50. Role of dopamine D(2) receptors for antipsychotic activity. Ginovart N; Kapur S Handb Exp Pharmacol; 2012; (212):27-52. PubMed ID: 23129327 [TBL] [Abstract][Full Text] [Related]
51. Lumateperone: New Drug or Same Old Drug With a New Dress? Limandri BJ J Psychosoc Nurs Ment Health Serv; 2020 Jun; 58(6):9-12. PubMed ID: 32463907 [TBL] [Abstract][Full Text] [Related]
52. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Kapur S; Seeman P Am J Psychiatry; 2001 Mar; 158(3):360-9. PubMed ID: 11229973 [TBL] [Abstract][Full Text] [Related]
53. Schizophrenia: an illness of distorted reality. Dean B Biologist (London); 2000 Sep; 47(4):202-6. PubMed ID: 11153121 [TBL] [Abstract][Full Text] [Related]
54. Comparison of the anti-dopamine D₂ and anti-serotonin 5-HT(2A) activities of chlorpromazine, bromperidol, haloperidol and second-generation antipsychotics parent compounds and metabolites thereof. Suzuki H; Gen K; Inoue Y J Psychopharmacol; 2013 Apr; 27(4):396-400. PubMed ID: 23427194 [TBL] [Abstract][Full Text] [Related]
55. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents. Newman-Tancredi A; Audinot V; Chaput C; Verrièle L; Millan MJ J Pharmacol Exp Ther; 1997 Jul; 282(1):181-91. PubMed ID: 9223553 [TBL] [Abstract][Full Text] [Related]